2nd Quarter - Report — CEPHEID for CEPHEID (2014)

Firm

CEPHEID

Client

CEPHEID

Income

—

Expenses

$50,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

See page threeLobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues

Lobbyist	Covered position, as disclosed
HALLIE CHRISTINE LEWIS	—
MICHELE M SCHOONMAKER	—

Contacted: Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); SENATE; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Agency for Healthcare Research & Quality (AHRQ); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Medicare/Medicaid MMM

See page 7Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues

Lobbyist	Covered position, as disclosed
HALLIE CHRISTINE LEWIS	—
MICHELE M SCHOONMAKER	—

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Medicare Payment Advisory Commission (MedPAC); Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); SENATE; Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

See page fiveLobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues

Lobbyist	Covered position, as disclosed
HALLIE CHRISTINE LEWIS	—
MICHELE M SCHOONMAKER	—

Contacted: Medicare Payment Advisory Commission (MedPAC); Centers For Disease Control & Prevention (CDC); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.